Axsome Therapeutics Reports Results of AXS-07 in MOMENTUM P-III Migraine Trial in Patients with History of Inadequate Response
Shots:
- The P-III MOMENTUM study involves assessing of AXS-07 vs PBO and rizatriptan in 1-594 patients in ratio (2:2:2:1) to treat a single migraine attack of moderate or severe intensity. Additionally- the trial was conducted pursuant to SPA with the FDA
- MOMENTUM P-III study results: met its co-primary endpoints with achievement in pain freedom (19.9% versus 6.7%)- absence of most bothersome symptom (36.9% vs 24.4%)- - pain relief @2 to 24 & @2 to 48 hrs (53.3% vs 33.5%- 43.9%) & (46.5% vs 31.1%- 36.5%)- rescue medication (23.0% vs 43.5%- 34.7%)- experience pain post @1.5hrs (60.5% vs 60.5% and 48.3%)- pain freedom from 2 to 24 hrs. (16.1% vs 11.2%- and 8.8%)
- AXS-07 oral- investigational medicine with dual of action under development for the acute treatment of migraine with expected NDA submission in H2’20 for acute treatment of migraine
Click here to read full press release/ article | Ref: Globe Newswire | Image: Signbox
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com